Cell Therapy News/Articles, page-14501

Nice find. Of particular note:

"The benefits of cell therapy range from a 6.2 units increase in left ventricular ejection fraction in MSC-HF[31] (which is more than the average increase after thrombolytic therapy in STEMI or after CRT in HF) to an improvement in quality of life (measured by the MLHFQ score) and 6-min walk distance (TAC-HFT[35]) and to a reduction in major adverse cardiac events (MACE) by 37% (ixCELL-DCM[30]), 77% (CONCERT-HF[32]), and 33%-65% (depending on the type of MACE) in DREAM-HF[33,34]. Certainly, these trials are not “disappointing”, nor are the aforementioned salubrious effects “minor” or “incremental”. In fact, considering that the treatment was given only once and the outcome measured 12 months later, these effects are quite remarkable. Those who deny it should name another therapy that produces any measurable change in clinical status in HF patients 12 months after one dose. It is time for this widespread misrepresentation to be rectified."